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Abstract
Circulating tumour cells (CTCs) refer to cells found in the peripheral blood, which are 
derived from the primary or secondary tumour. They serve as an alternative to study the 
biology of the primary tumour especially when tissue biopsy is not available. However, 
major challenges in CTC analysis are the rarity of these cells and the purity of the isolated 
population. The advancement in technologies allows detection and enrichment of suf-
ficiently pure CTCs at the single-cell level, facilitating downstream molecular charac-
terisation. Single CTC analysis allows detection of key mutations that may be critical to 
disease management and helps to address the intercellular differences among tumour 
cells. In this chapter, we discuss the technologies for CTC isolation and the use of CTCs in 
achieving early detection and prognosis of cancer, real-time monitoring of cancer therapy 
and tailoring of personalised treatments.
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1. Introduction
Cancer is a leading cause of death in many countries [1]. According to World Health Organisation, 
approximately one in six deaths is attributable to cancer. The development of cancer is a multi-
stage process. Briefly, normal cells undergo transformation into tumour cells, which are defined 
by various hallmarks including the ability to sustain proliferative signals, evade growth sup-
pressors, promote replicative immortality, avoid cell death and immune destruction, induce 
angiogenesis and activate invasion and metastasis [2]. This cellular transformation results in 
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uncontrolled proliferation and enables tumour cells to migrate from their primary organ to a 
distant organ, a process known as metastasis. In 90% of cancer patients, death occurs because of 
metastasis [3, 4].
According to Cancer Research UK, 46% of patients in England are diagnosed in the advance 
stages of disease, leading to less effective treatment outcomes. To reduce the number of deaths 
caused by cancer, detection at an early stage of disease development is critical so that clinical 
intervention can come in place to improve the chances of survival for cancer patients. The 
diagnosis of cancer involves multiple tests including tissue biopsy, liquid biopsy, imaging 
scans, genetic tests and an examination of medical history. Tissue biopsy is regarded as the 
gold standard for the clinical diagnosis of cancer [5, 6], despite the invasiveness and inconve-
nience of collecting the biopsy sample.
In recent years, liquid biopsy is increasing being used for the detection of cancer because it 
only requires a routine draw of blood and is less invasive compared to tissue biopsy, which 
may also not be repeatedly done safely or feasibly [7]. Liquid biopsy includes the analysis 
of circulating tumour cells (CTCs), circulating cell-free DNA (cfDNA) or exosomes present 
in the patient’s blood [8]. CTCs, in particular, have garnered much attention for its potential 
clinical utility. CTCs are cells disseminated from the primary or secondary tumour into the 
peripheral blood and are associated with the development of metastasis. They are precursors 
of secondary tumour formation and may carry key information relating to the mechanism 
of metastasis. They are approximately 12–25 μm [9] and present in extremely low numbers 
(typically 1–10 CTCs per 10 ml of blood or ~1–100 CTCs per 109 blood cells) [10–12]. The 
number of CTCs found in the blood varies with the type and stage of cancer and the treatment 
provided [13]. Typically, patients in the advanced stages of cancers have higher number of 
CTCs [14]. CTCs of different cellular morphology may exist in the blood and these include the 
epithelial CTCs, epithelial-to-mesenchymal (EMT) CTCs and mesenchymal CTCs. Moreover, 
the mutations found in CTCs are often concordant with the primary tumour [15–17], suggest-
ing that the genetic composition of CTCs is similar to the primary tumour. Thus, CTCs has the 
potential to be used as a ‘surrogate’ to study the biology of cancer cells.
In cancer treatment, drug resistance is a major concern. The failure of chemotherapeutic drugs to 
work in patients lies in the heterogeneity and complexity of cancer cells [18, 19]. Cancer stem cells 
are resistant to chemotherapy and contribute to the intra-tumoural heterogeneity [20]. Therefore, 
there is a need for molecular profiling of tumour cells at the single-cell level to better address the 
intra- and inter-cellular differences in cancer cells and enable clinicians to have a better picture of 
the disease complexity. While paired tumour/normal tissues is the gold standard for molecular 
analyses of tumour [21], CTCs may provide information on the dynamic changes in tumour cells 
when blood is extracted at different times, which cannot be achieved in tissue biopsy. In addi-
tion, where tissue is not easily accessible, CTCs may provide a diagnostic window.
However, the main challenges of CTC research are that these cells are extremely rare and the 
population of isolated CTCs may not be pure due to contamination with white blood cells 
(WBCs). Therefore, highly sensitive and specific technologies are required to isolate CTCs effi-
ciently. Over the past decade, microfluidics technology has greatly advanced the enrichment 
and isolation of CTCs from whole blood containing red blood cells (RBCs) and WBCs [22]. 
Microfluidics deals with the behaviour of fluid passing through the microchannels [23, 24]. It 
makes use of the laminar flow of fluid in the microchannels to manipulate the fluid to achieve 
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cell separation. Furthermore, because of the small space and short flow distance in the micro-
device, microfluidics-based technologies consume small amounts of reagents and greatly 
increase the speed and throughput of blood sample processing, allowing clinical adoption. 
The use of microfluidics facilitates the integration of downstream molecular characterisation 
of CTCs, which will enhance our understanding on the complexity of cancer development and 
enable clinicians to develop better therapeutic strategies to eradicate cancer cells and improve 
the overall survival of patients. In this chapter, we discuss the technologies for CTC isolation 
and the use of single-cell analysis in achieving early detection and prognosis of cancer, real-
time monitoring of cancer therapy and tailoring of personalised treatments.
2. Technologies for enrichment and isolation of CTCs
Many technologies have been developed to enrich and isolate CTCs from the peripheral 
blood. In most methods, CTCs are separated from the blood cells based on their biological 
properties and/or physical properties such as size, deformability, density and electric charge. 
Conventional CTC enrichment systems such as fluorescence activated cell sorters (FACs) 
have been used to separate CTCs from whole blood based on the expression of cell surface 
protein markers [25]. Technologies that isolate CTCs based on physical properties also exist. 
For instance, ISET and ScreenCell use a filtration system to separate the slightly larger CTCs 
(12–25 μm) from the smaller WBCs (7–15 μm) and RBCs (8 μm) [9]. CTCs and mononuclear 
cells have a density (<1.077 g/ml) lower than other blood cells (>1.077 g/ml), allowing layered 
separation of CTCs [6]. CTCs and blood cells exhibit differences in deformability, allowing 
them to be separated [26]. The dielectric properties of CTCs are different from normal blood 
cells, allowing separation of CTCs when the cells are subjected to a non-uniform electric field 
[6, 27]. However, these conventional CTC enrichment methods suffer from limited ability to 
process large volumes of blood, limited detection sensitivity, inherent losses and poor recovery 
of viable CTCs, low throughput and insufficient purity due to contamination with WBCs [6].
2.1. Use of microfluidics in CTC enrichment
To overcome these limitations, microfluidics technology offers an alternative platform for 
isolating CTCs with improved detection sensitivity, high recovery rate, high efficiency and 
throughput. Each microfluidics platform has its advantages and limitations (Table 1). In 2004, 
US Food and Drug Administration approved the clinical use of CellSearch system (Veridex) 
for CTC detection in epithelial cancer types such as breast [28], colorectal [29] and prostate 
cancer [30] for purposes of prognostication. This system uses immunomagnetic and fluores-
cence imaging technology to enrich and enumerate CTCs from 7.5 ml of whole blood based on 
the expression of specific proteins in CTCs [31, 32]. CTCs are first separated from other blood 
cells using magnetic iron nanoparticles coated with antibodies targeted against EpCAM (an 
epithelial cell adhesion molecule present on the cell surface of CTCs). Subsequently, cells are 
stained with antibodies targeted against cytokeratin (CK; a protein found in the cytoplasm 
of CTCs) and CD45 (a cell surface protein found exclusively on WBCs) to differentiate CTCs 
from contaminating WBCs. DAPI (4′,6-diamidino-2-phenylindole) is also used to stain the 
nuclei of CTCs and WBCs. Finally, a magnetic field is applied to collect the CTCs, which are 
identified by positive expression of EpCAM and CK and negative expression of CD45.
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System Separation principle Strengths Weaknesses References
Antibody-based capture
CellSearch Positive selection for 
EpCAM, CK8/CK18/
CK19 and negative 
selection for CD45
• Food and Drug adminis-
tration (FDA)-approved 
for clinical use
• Unable to capture 
tumour cells that 
lack EpCAM 
expression
• Only applicable 
to cancers with 
epithelial origin
• Cells are not viable 
after isolation
[28–30]
CTC-chip EpCAM-based • Sample does not require 
pre-processing
• Cells remain intact and 
viable after isolation
• Unable to capture 
tumour cells that 
lack EpCAM 
expression
• Only applicable 
to cancers with 
epithelial origin
• Unable to recover 
tumour cells with 
100% purity
[33]
CTC-ichip Size-based separation 
followed by negative 
depletion of white 
blood cells with CD45 
and CD66b magnetic 
beads
• Fast processing time 
(8 ml/h)
• Has the potential to 
capture CTCs from any 
cancer type.
• Cells remain intact and 
viable after isolation
• Unable to capture 
tumour cells that 
are smaller or 
similar in size to 
blood cells.
• Unable to recover 
tumour cells with 
100% purity
[51, 52]
IsoFlux EpCAM-based • Higher sensitivity of 
detecting CTCs than 
CellSearch system
• Unable to capture 
tumour cells that 
lack EpCAM 
expression
• Only applicable 
to cancers with 
epithelial origin
[53]
Magnetic Sifter EpCAM-based • Allows rapid imaging of 
captured cells on a small 
area
• Cells remain intact and 
viable after isolation
• Reduces sample 
losses with minimal 
pre-processing
• Unable to capture 
tumour cells that 
lack EpCAM 
expression
• Only applicable 
to cancers with 
epithelial origin
[54]
GEDI 
microdevice
Prostate-specific 
membrane antigen 
(PSMA)/HER2-based
• Higher sensitivity of 
detecting CTCs than 
CellSearch system
• Device geometry reduces 
capture of WBCs
• Only applicable 
to prostate cancer, 
breast cancer, 
gastric cancer
• Unable to recover 
tumour cells with 
100% purity
[43, 55, 56]
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System Separation principle Strengths Weaknesses References
Label-free capture
ClearCell FX
(spiral chip)
Size-based • Fast processing time 
(3 ml/h)
• Cells remain intact and 
viable after isolation
• Cost-effective
• Has the potential to cap-
ture CTCs from various 
cancer types.
• Unable to capture 
tumour cells that 
are smaller or 
similar in size to 
blood cells.
• Unable to recover 
tumour cells with 
100% purity
[11, 40]
Microfluidic 
biochip
Size-based • Fast processing time 
(7.5 ml of blood in 3 h)
• Allows single-cell 
isolation
• Able to isolate viable 
CTCs with 100% purity
• Has the potential to cap-
ture CTCs from various 
cancer types.
• Limited number of 
cell chambers for 
imaging
• Unable to capture 
tumour cells that 
are smaller or 
similar in size to 
blood cells.
[16, 17]
Vortex Size-based • Fast processing time 
(7.5 ml of blood in 20 min)
• Cells remain intact and 
viable after isolation
• Has the potential to cap-
ture CTCs from various 
cancer types.
• Unable to recover 
tumour cells with 
100% purity
• Low CTC capture 
efficiency
• Unable to capture 
tumour cells that 
are smaller or 
similar in size to 
blood cells.
[57]
Microfluidic 
device for 
deformability-
based cell 
classification
Size and 
deformability-based
• Cells remain intact and 
viable after isolation
• Cost-effective
• Has the potential to cap-
ture CTCs from various 
cancer types.
• Unable to recover 
tumour cells with 
100% purity
[35]
DEPArray Electric charge-based • Allows single-cell 
isolation
• Able to isolate viable 
CTCs with 100% purity
• Has the potential to cap-
ture CTCs from various 
cancer types.
• Limited throughput
• Large amount of 
sample loses
[58, 59]
Abbreviations used are: CTC, circulating tumour cell; EpCAM, epithelial cell adhesion molecule; CK, cytokeratin 
proteins.
Table 1. Comparison of selected microfluidics systems used for enriching CTCs.
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In 2007, a microfluidics chip developed for CTC enrichment and isolation, known as CTC-chip, 
was introduced [33]. In this system, CTCs are captured as blood flows through the microchan-
nel containing EpCAM antibody-coated microposts [33]. CTCs are captured with ~50% purity 
and sample processing takes 1–2 ml/h. Following CTC-chip, a broad range of microfluidic 
devices were generated to isolate CTCs based on physical size, density, deformability [34–41] 
or antibody-mediated CTC capture in surface functionalised microchannels [33, 42–47].
Although the affinity binding methods (e.g. CellSearch, CTC-chip) may isolate CTCs of better 
purity than the physical methods, the strong antibody-antigen interaction in the microdevice 
may affect the recovery of viable CTCs [11, 48] and hinder subsequent downstream analy-
sis. Additionally, affinity binding methods will lose out on the subpopulation of CTCs that 
have down-regulated expression of epithelial markers (e.g. EpCAM) such as the mesenchy-
mal CTCs, resulting in an underrepresentation of the actual CTC count in the blood [11, 49]. 
Therefore, the limitations imposed by affinity binding methods prompt the development of 
label-free microfluidic devices that can isolate CTCs with increased purity and viability.
To efficiently separate CTCs from the large pool of RBCs and WBCs, a spiral microfluid-
ics chip was introduced in 2013 [11, 50]. The spiral microchannel (500 μm width × 160 μm 
height) consists of two inlets and two outlets over a length of ~10 cm. Blood (diluted 2–2.5×) is 
pumped into the outer inlet while sheath fluid is pumped through the inner inlet. The addi-
tional sheath fluid in the spiral chip facilitates the Dean migration of large volume of RBCs in 
a well-controlled manner, thus allowing high haematocrit samples (20–25%) to be processed. 
In spiral microchannel, CTCs and other blood cells experience Dean drag forces in addition 
to inertial lift forces and the combined effects cause hydrodynamic focusing of the cells to 
specific region of the microchannel. The larger CTCs are focused near the inner wall of the 
channel while smaller WBCs and RBCs are focused along the outer wall, leading to efficient 
size-based isolation of CTCs [50]. Furthermore, the spiral chip is able to recover >85% spiked 
cancer cells and deplete almost 100% of WBCs from the blood sample [11, 50]. Trypan blue 
staining showed that most of the recovered cells (>98%) are viable [11]. Therefore, the spiral 
chip allows continuous isolation of CTCs in a single step with high sensitivity, recovery and 
throughput (3 ml of blood can be processed in an hour) [11]. The spiral chip is also designed 
to have large microchannel dimensions and high flow rate to prevent non-specific binding of 
CTCs to the walls and eliminate any potential clogging issues [11].
2.2. Microfluidics and single CTC isolation
Most microfluidics systems isolate CTCs in bulk rather than individually. The bulk analysis 
of CTCs may mask the presence of key mutations that are critical to disease progression, 
indicating the need for single-cell analysis. To isolate and study CTCs at the single-cell level, 
approaches such as micropipette aspiration [60, 61] and laser microdissection [62] have been 
used to manually select the individual CTCs. However, these methods are laborious and suf-
fer from low throughput, making them less suitable for clinical use. Commercial platforms 
such as DEPArray (Silicon Biosystems), which rely on the dielectric properties of CTC for 
single-cell isolation, suffer from large amount of sample losses [58].
To address these limitations, Yeo et al. developed a microfluidics device capable of perform-
ing high throughput, selective isolation of individual viable CTCs with 100% purity amidst a 
Liquid Biopsy18
large population of WBCs [17]. The separation efficiency is high because as few as 1 CTC in 
20,000 WBCs can be recovered. Prior to starting the run, the cell suspension is stained with 
specific fluorophore-conjugated antibodies such as CK or CD45 to facilitate the differentiation 
of CTCs from WBCs. The device works on the principle of hydrodynamic focusing to restrict 
cells to flow in a single stream and hold them passively in active control cell chambers that 
are positioned along the outer curvature of the channel. CTCs and other blood cells flowing 
through the channel will experience a slight centrifugal force that facilitates their entry into 
the cell chambers. Because the microfluidics biochip is integrated into a microscope, the cell 
sitting in the chambers can be observed under the microscope to determine whether it is a 
CTC or WBC based on size or staining outcome. Each chamber holds 1 cell at a time and each 
is connected to a control line that can be activated to eject the selected cell back into the main 
channel and into the collection well. In this manner, the cells isolated in the chambers can be 
ejected sequentially so that each cell can be recovered individually. To maximise the recovery 
of rare CTCs, the effluent of each run is recycled back into the device for three times. The 
device is able to process 7.5–8 ml of blood in 3 h [16], facilitating the enumeration of CTCs 
in clinical blood samples in a short period of time. This method also allows the collection of 
single CTCs for downstream molecular profiling.
3. Clinical applications of CTCs
Given the convenience and ease of obtaining blood samples from cancer patients, CTCs are 
currently being adopted for clinical practice. This is especially the case when tissue biopsy 
samples are not readily available. With current technologies, CTCs can be isolated in bulk or 
individually for studies on disease progression and therapeutic treatment. Single-cell analysis 
offers several advantages over pooled cell analysis. First, single-cell analysis is able to detect 
critical driver mutations for drug response that are present in low frequency, which may be 
masked in pooled cell analysis since the mutations may only be present in a subset of clones. 
For instance, in stage IV non-small cell lung cancer (NSCLC) patients who developed resistance 
after tyrosine kinase inhibitor (TKI) treatment, sequencing of single CTC revealed the presence 
of epidermal growth factor receptor (EGFR) mutation T790 M that confers resistance in a sub-
set of CTCs isolated from each patient (0–3 CTCs carry the mutation among <10 CTCs isolated 
per patient) [17]. Determining the mutation status of EGFR in NSCLC patients is important 
for patient stratification and treatment (see Section 3.4). Second, single-cell analysis reveals the 
heterogeneity in gene mutations and chromosomal copy number aberrations (CNA) among 
tumour cells while bulk cell analysis would have average out the signals. In metastatic breast 
cancer, a sequencing analysis of 40 single CTCs from five patients demonstrated heteroge-
neous mutations in four genes, phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA), 
tumour protein P53 (TP53), oestrogen receptor 1 (ESR1) and KRAS [63]. Within the same meta-
static breast cancer patient, not all CTCs harbour the particular mutation and different patients 
harbour different gene mutations [63]. In small cell lung cancer (SCLC) patients, chromosomal 
CNA profiling of individual CTCs obtained at pre-treatment can predict whether the patient 
is sensitive or refractory to subsequent chemotherapy at an accuracy of 83.3% [64], facilitating 
clinical decision-making. Third, single-cell analysis facilitates the study of clonal diversity and 
mutation evolution over the course of chemotherapy, which is difficult to achieve in bulk cell 
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analysis [65, 66]. In triple negative breast cancer (TNBC) patients, single-cell DNA sequencing 
revealed that chemoresistant patients carry pre-existing mutations and CNA that were adap-
tively selected in response to chemotherapy [65]. Single-cell RNA sequencing also found that 
chemotherapy induces transcriptional reprogramming to favour the resistant phenotype in 
TNBC patients who develop chemoresistance [65]. Thus, single-cell analysis provides a better 
resolution of the tumour profile than pooled sample analysis. More importantly, single-cell 
analysis of CTC can address the heterogeneous profile of cancer cells at the DNA, RNA and 
protein level and provide insights in the mechanism of metastasis and drug resistance. Here, 
we discuss the applications of CTCs that aid in the management of cancer and how single CTC 
analysis can contribute to achieving personalised medicine in the future.
3.1. Biomarker for early detection of cancer
The presence of CTCs in the peripheral blood acts as a biomarker for the early detection of 
cancer. Thus, the enumeration of CTC is important for cancer screening, especially in patients 
who at a higher risk of developing cancer due to genetic predisposition or disease state. The 
effective use of CTC enumeration in the detection of early-stage cancer has been demonstrated 
in patients with chronic obstructive pulmonary disease (COPD), who are at a high risk of 
developing lung cancer [5, 67]. Because of the risk, COPD patients are monitored annually for 
the development of lung cancer using computed tomography (CT) scan. In a subset of COPD 
patients without cancer diagnosis, CTCs were found in the peripheral blood. After 1–4 years 
of CTC detection, lung nodules were indeed detected by CT scan, leading to the diagnosis of 
early-stage lung cancer. Large-scale clinical studies are being done to further validate the use 
of CTCs as a diagnostic tool for the early detection of cancer [5]. Therefore, CTC can serve as 
a potential biomarker for the early detection of cancer so that prompt treatment intervention 
can come in place to improve the overall health of patients.
3.2. Prognostic marker for overall survival and metastasis
The number of CTCs found in the blood can indicate the state of the disease. Patients in later 
stages of cancer (e.g. metastatic cancer patients) have higher number of CTCs as compared to 
patients in the early stages of cancer [14, 68, 69]. Furthermore, the number of CTCs can vary 
with chemotherapy treatment, allowing clinicians to use CTC counts to determine the treatment 
efficacy and estimate the overall survival and risk of metastatic relapse. A study on early breast 
cancer patients [70] measured the number of CTCs before and after adjuvant chemotherapy 
demonstrated that the persistent presence of CTCs after chemotherapy is associated with poor 
disease-free survival and overall survival. Moreover, prognosis was worst in patients with >5 
CTCs per 30 ml of blood [70]. Similarly, studies in lung cancer patients also showed that higher 
number of CTCs was significantly correlated to shorter survival [32, 71–73]. Specifically, the 
presence of >8 CTCs per 7.5 ml of blood after treatment strongly correlated with worse survival 
in small cell lung cancer patients [74]. In prostate cancer, therapeutic treatment resulting in 
CTC level dropping from >5 to <5 in 7.5 ml of blood is indicative of better overall survival [55]. 
Thus, the prognostic cut-off value for CTC is dependent on the type of cancer.
Additionally, CTC enumeration can be used for predicting the risk of metastasis. In non-
metastatic colorectal cancer patients, those with >5 CTCs per 2 ml of blood were more likely 
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to develop distant metastasis than those with <5 CTCs [69]. The strong correlation between 
CTC count and metastasis relapse have been shown in other types of cancers as well includ-
ing bladder cancer [75, 76], liver cancer [77] and oesophageal cancer [78]. Thus, these patients 
may benefit more from early treatment.
3.3. Monitoring treatment response and disease progression
Sequential tracking of CTC number during treatment may inform on treatment response and 
disease progression, providing important information to clinicians on whether the treatment is 
suitable for the cancer patient. In advanced NSCLC patients, a significant decrease in CTC count 
after the second cycle of chemotherapy strongly correlated with better overall survival and 
progression-free survival [32, 79, 80]. However, a lack of decline in the number of CTCs after 
chemotherapy may suggest that the patient has developed resistance against the specific drug. 
Therefore, alternative treatment strategies have to be adopted to curb disease progression and 
improve patient survival. Another potential application may be the detection of early relapse 
with regular monitoring of the CTC count in post-surgical cancer patients. This may allow early 
detection and timely clinical intervention to treat the disease when the disease burden is less.
3.4. Identification of therapeutic targets and drug resistance
Given the continuous improvement in microfluidics technology, Khoo et al. demonstrated 
that patient-derived CTCs could be cultured into CTC clusters in vitro using a microfluidic 
culture device [81]. Prior enrichment of CTCs and supplements of growth factors are not 
required, thereby shortening the processing time. Using blood samples from the same patient, 
CTCs are co-cultured with immune cells in specially formulated microwells to promote the 
formation of CTC cluster within 2 weeks. The success rate of CTC cluster formation is approx-
imately 50%. With the development of this platform, drug screening can be readily conducted 
and this can facilitate the discovery and testing of novel drugs that are more efficacious in the 
treatment of cancer. Furthermore, drug responses can be monitored with varying doses of 
drug to determine the optimal dose for individual patient.
With the advent of next-generation sequencing, the molecular profile of single CTCs can be 
obtained at the DNA, RNA and protein level. The genomic profile of single CTCs can be 
compared to normal or non-malignant cells to identify genes that are differentially expressed, 
which may mediate the process of metastasis and become potential therapeutic targets. The 
whole genome sequencing of individual CTCs can reveal genetic alterations such as muta-
tions, copy number variations and single nucleotide polymorphisms that may confer selective 
advantage to tumour cells [82]. The presence of specific gene mutations in CTCs confers drug 
resistance and determines the type of treatment to be given to patients. This information is 
particularly useful when the mutation profile of CTC is concordant with the primary tumour. 
For example, the CTCs of NSCLC patients harbouring the EGFR T790 M mutation confer 
resistance to TKI treatment (e.g. gefitinib) [83]. Tracking changes in the CTC count and muta-
tion frequency over the course of treatment allows real-time monitoring of treatment sensitiv-
ity and resistance. The early detection of these mutations may provide alternative treatment 
strategies for NSCLC patients and optimise disease management, leading to improved clini-
cal outcomes [17]. Thus, determining the mutation status of EGFR is crucial since it allows 
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clinicians to select patients who will benefit from TKI treatment. Furthermore, understanding 
the key mutations behind drug resistance may help to decipher the mechanism and signalling 
pathways involved in resistance.
The transcriptome of single CTCs also provides information on the identification of thera-
peutic targets and drug resistance. In prostate cancer, analysis of the mRNA profile in CTCs 
is required to determine drug sensitivity or resistance. Specifically, the expression of Arv7 
mRNA, a truncated form of androgen receptor that remains constitutively active, in CTCs 
is predictive of anti-androgen therapy failure with enzalutamide and abiraterone [84, 85]. In 
prostate cancer patients with Arv7 expression, alternative drugs such as taxanes are used for 
treatment [86–89]. Additionally, RNA-seq of CTCs can reveal miRNAs that are dysregulated 
in cancers, making these miRNAs potential targets for cancer therapy.
The expression profile of proteins in single CTCs also plays a role in determining the anti-
cancer treatment. For example, oestrogen receptor (ER) is a primary target in the treatment 
of breast cancer patients. Thus, primary tumours of breast cancer patients are stratified 
as ER+ or ER- and hormonal therapy is given based on the status of ER expression in the 
primary tumour. However, breast cancer patients with ER+ primary tumours can harbour 
ER- CTCs in the blood, which may escape the hormonal therapy [90]. Similarly, metastatic 
breast cancer patients with HER2+ primary tumours can carry HER2- CTCs in the blood 
[91–93]. Because of this discordance, HER2-targeted therapies may only be effective against 
the primary tumour but not the CTCs. Thus, cancer cells will not be fully eradicated and this 
may lead to metastatic cancer relapse. In this situation, additional treatment strategies have 
to be adopted to target the CTCs, on top of the primary tumour. Therefore, the monitoring 
of genetic aberrations is important in identifying acquired mutations that confer resistance 
to drug therapy.
The expression status of programmed death ligand 1 (PD-L1) in CTCs aids in identifying the 
groups of patients who are likely to benefit from the immunotherapy as well as predicting 
the response to the immunotherapy. Tumour cells express PD-L1 that binds to PD-1 receptor 
found on the surface of activated T cells and B cells to induce an immunosuppressive effect 
by reducing cytokine production and immune cells proliferation [94, 95]. It was previously 
shown that metastatic tumour cells have higher PD-L1 expression than primary tumour 
cells [96]. In breast cancer, the detection of CTCs expressing PD-L1 indicates that patients 
carry metastatic cells that have the potential to evade immune destruction [94]. Breast cancer 
patients with a high frequency of PD-L1(+) CTCs are more likely to benefit from anti-PD-
L1 immunotherapy than patients with PD-L1(−) CTCs [94]. In a study on NSCLC patients, 
PD-L1 expression on CTCs was monitored throughout the course of immunotherapy [97]. 
After 6 months of therapy, patients with PD-L1 expression in CTCs had poor prognosis while 
patients without PD-L1 expression in CTCs benefitted from the therapy [97].
Given the intra-tumoural and inter-tumoural heterogeneity and dynamic nature of cancer, 
single-cell analysis of CTC in circulation may provide information on the evolution of tumour 
and how they evade drug therapy and immune response (Figure 1). This enables clinicians 
to have a more holistic view of the disease complexity and more efficient targeting of cancer 
cells, moving towards the development of personalised therapy for individual patients.
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3.5. Comparing CTC with cell-free DNA and exosome
Apart from CTCs, other liquid biopsy markers that confer diagnostic and prognostic rel-
evance include the cell-free DNA (cfDNA) and exosomes. Each marker has its own strengths 
and weaknesses (Table 2). cfDNA refers to DNA released from necrotic and apoptotic cells 
and they can be found in blood plasma. Cancer patients usually have higher concentration 
of cfDNA compared to healthy individuals [98, 99]. Most cfDNAs in the blood plasma are 
around 70–200 bp long [100, 101]. cfDNA includes the circulating tumour cell DNA (ctDNA), 
which are released from CTCs. The fraction of ctDNA contributing to cfDNA is small although 
usually higher in late stage cancer patients (>5–10%) than patients in the early stages of cancer 
Figure 1. A proposed scheme of how single-cell analysis of CTCs may address tumour heterogeneity. Heterogeneous 
tumour cells are colour-coded. Heterogeneity stems from genetic or epigenetic changes that confer selective advantage 
to the tumour cells. Several strategies of single-cell analysis can be adopted to dissect the heterogeneity of tumour cells. 
Sequential analyses of individual CTCs aids in the monitoring of therapeutic response, tumour evolution and detection 
of treatment-resistant cells.
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(<1%) [98, 102, 103]. A large fraction of cfDNA comes from non-malignant cells that contain 
wild type DNA. Because of this issue, highly specific and sensitive technologies are required 
to isolate cfDNA that originates from tumour cells.
The isolated cfDNAs are subjected to sequencing analysis using next-generation sequencing 
platforms to identify tumour-associated genetic mutations or epigenetic changes. For example, 
in a large-scale study of NSCLC patients on gefitinib treatment, cfDNA was used as a surrogate 
of tissue biopsy to identify the EGFR mutations, demonstrating its clinical utility [100, 104]. 
A comparison on the frequency of mutation detection between cfDNA and CTC revealed 
that cfDNA showed a higher frequency of the mutation from the same patient [100, 102], 
suggesting that cfDNA is more effective in detecting these genetic changes. Another advan-
tage that cfDNAs have over CTCs is that cfDNAs can be obtained from bio-banked fluids such 
as frozen plasma whereas CTCs can only be obtained from peripheral blood [100]. However, 
the use of cfDNAs as a liquid biopsy marker also poses several limitations. First, because 
cfDNA can originate from any cell type including normal cells and tumour cells, there will be 
a high background of wild type DNA and thus isolating a pure population of the rare tumour-
derived cfDNA is technically challenging. The abundance of wild type DNA may mask the 
detection of low copy genetic mutations that could be important for early detection of cancer 
or drug resistance. Second, molecular profiling of cfDNAs is restricted to the DNA level as the 
characterisation of the transcriptome and proteome is not possible [100].
Liquid biopsy Strengths Weaknesses
Circulating 
tumour cell (CTC)
• Allows downstream molecular analysis 
and in vivo or in vitro functional studies
• Able to evaluate the DNA, RNA and 
protein profile of tumour cells
• Able to study the cellular phenotype, 
morphology and protein localisation
• Extremely rare and challenging to isolate
• Heterogeneous population of CTCs may lead to 
false positive and false negative results
Cell-free DNA 
(cfDNA)
• High sensitivity in detecting genetic 
aberrations
• Challenging to isolate pure population of 
cfDNAs
• Molecular characterisation is limited to genomic 
DNA and unable to evaluate the RNA and 
protein profile
• Unable to perform phenotypic and functional 
studies
Exosome • Abundant in the plasma
• Allows downstream molecular analysis 
and functional studies
• Able to evaluate the DNA, RNA and 
protein profile of tumour cells
• Allows analysis of inflammatory, 
stromal and other systemic changes
• Challenging to isolate pure populations of 
tumour-derived exosomes
• Unable to perform phenotypic studies
Table 2. Comparison of the liquid biopsy markers.
Liquid Biopsy24
Exosomes are membrane-bound microvesicles derived from multivesicular bodies (MVBs) and 
secreted into the extracellular environment through fusion of MVB to the plasma membrane [8, 100]. 
They mediate cell-cell communication by transferring biomolecules such as DNA, RNA, proteins 
and lipids from the donor cell to the recipient cell [105]. Exosomes can originate from many cell 
types including tumour cells, epithelial cells, fibroblasts, neuronal cells, haematopoietic cells and 
adipocytes [8, 106]. Most exosomes are around 30–200 nm and are present in large quantities in 
biological fluids including serum, plasma, urine and saliva [8, 100]. Tumour cells release tens of 
thousands of exosomes in a day, resulting in hundreds of billions of exosomes per ml of plasma 
[100, 107]. Since exosomes are abundant, they are easier to isolate compared to CTCs and cfDNAs. 
However, there is a lack of efficient tumour exosome enrichment method [108] because the isola-
tion of exosomes is largely based on exosome-specific surface markers [100, 109], which do not 
distinguish between exosomes derived from tumour cells and normal cells.
Because exosomes carry the DNA, RNA and protein content from tumour cells (i.e. cell of 
origin), they are useful diagnostic and prognostic tools of cancer. Similar to CTCs and cfDNAs, 
exosomes can be subjected to DNA analysis to determine the genetic aberrations and muta-
tional landscape of tumour cells. Additionally, the RNA and protein profiles of tumour exo-
somes can be characterised to provide insights into the biology of tumour cells. For example, 
analysis of exosomal mRNA and proteins allows real-time monitoring of therapeutic response 
and drug resistance in glioblastoma patients [110, 111]. The up-regulated expression of a panel 
of serum-derived exosomal miRNAs (miR-1246, miR-4644, miR-3976, miR-4306) serves as 
a biomarker for the diagnosis of pancreatic cancer [112]. The down-regulated expression of 
miR-92a is associated with high risk of cancer relapse in hepatocellular carcinoma patients 
[113]. Furthermore, previous reports showed that tumour exosomes play a role in suppressing 
immune response, promoting tumour cell growth, angiogenesis and metastasis [100, 114–116]. 
Similar to CTCs, molecular profiling of exosomes provides insights into the mechanism of 
metastasis and drug resistance.
3.6. Barriers to adoption of CTC as a clinical test
Although CTCs have numerous potential clinical applications, the incorporation of CTCs into 
routine clinical practice still faces several challenges. First, there is a lack of reproducibility in 
CTC enumeration when different measurements were taken from the same patient [117]. This 
variation is likely caused by the extremely low frequency of CTCs in peripheral blood, where 
>90% of patients with localised diseases and up to 30–40% of patients with metastatic disease 
do not have >5 CTCs per 7.5 ml of blood [117, 118]. A difference of 1 CTC may lead to different 
stratification and prognostic outcome [117]. A possible solution to improve the CTC yield is 
to process larger volume of blood sample from cancer patients [117, 119]. Second, there is a 
lack of standardisation across the myriad of CTC detection platforms in defining and isolating 
CTCs [120, 121], resulting in variability of CTC count. Studies comparing EpCAM-dependent 
and EpCAM-independent CTC enrichment methods using blood samples from the same 
patient showed that EpCAM-independent methods generate a higher CTC count compared 
to the CellSearch system [117]. Thus, a universal quality control system is required for detect-
ing and isolating CTCs across the various platforms so as to benchmark the reliability of these 
methods [117, 120]. Cross-validation studies on CTC enumeration from different laboratories 
Profiling Circulating Tumour Cells for Clinical Applications
http://dx.doi.org/10.5772/intechopen.79228
25
will also minimise the inter-observer variation [117]. Lastly, the current CTC isolation tech-
nologies have limited sensitivity and are not applicable to all types of cancer [117]. Therefore, 
before CTCs can be fully adopted for routine clinical use, well-designed appropriately pow-
ered validation studies are required.
4. Conclusion
Late clinical diagnosis and chemotherapy resistance are the main factors leading to reduced 
chances of survival for cancer patients. To combat cancer, CTCs provide invaluable informa-
tion on the status of the disease and the likely outcome of chemotherapeutic treatment. The 
enumeration of CTCs allows early detection of cancer, prognosis and real-time monitoring of 
chemotherapy treatment. The single-cell analysis of CTCs provides a wealth of genetic infor-
mation that enables better understanding of the disease complexity for individual patients 
and provides the opportunity for the development of personalised treatment. To aid in deliv-
ering better therapeutic medicine, current technologies allow CTCs to be cultured in vitro 
for the identification of novel therapeutic targets and optimal drug dosage for individual 
patients. Therefore, the molecular characterisation of CTCs is important for improving the 
clinical outcomes in cancer patients.
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